Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) EBITDA Margin (2019 - 2025)

Historic EBITDA Margin for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to 2928.84%.

  • Kymera Therapeutics' EBITDA Margin fell 13662300.0% to 2928.84% in Q3 2025 from the same period last year, while for Sep 2025 it was 124181.51%, marking a year-over-year increase of 1243677700.0%. This contributed to the annual value of 7251.32% for FY2024, which is 70699200.0% down from last year.
  • Latest data reveals that Kymera Therapeutics reported EBITDA Margin of 2928.84% as of Q3 2025, which was down 13662300.0% from 664.67% recorded in Q2 2025.
  • Kymera Therapeutics' 5-year EBITDA Margin high stood at 202.77% for Q4 2024, and its period low was 2928.84% during Q3 2025.
  • Over the past 5 years, Kymera Therapeutics' median EBITDA Margin value was 290.29% (recorded in 2025), while the average stood at 509.28%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first surged by 2981200bps in 2021, then tumbled by -13662300bps in 2025.
  • Over the past 5 years, Kymera Therapeutics' EBITDA Margin (Quarter) stood at 225.3% in 2021, then increased by 7bps to 210.06% in 2022, then soared by 88bps to 26.04% in 2023, then skyrocketed by 879bps to 202.77% in 2024, then plummeted by -1544bps to 2928.84% in 2025.
  • Its last three reported values are 2928.84% in Q3 2025, 664.67% for Q2 2025, and 290.29% during Q1 2025.